Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...
A new era at IBD began nearly a year ago with the launch of MarketSurge, a makeover of the MarketSmith charting and research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback